PD-L1 Inhibitor Nivolumab Works Well in New Mesothelioma Study
A study of the PD-L1 inhibitor nivolumab showed “safety and efficacy” in mesothelioma patients who failed with other treatments. Nivolumab…
New drugs for mesothelioma, improvements in diagnostic tools and clinical trials give cancer patients more than a fighting chance. Read now.